Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers

A 14-day, randomized, open, phase I clinical trial was designed to examine possible pharmacokinetic interactions between rifabutin and two other antibiotics, azithromycin and clarithromycin, used in the treatment of Mycobacterium avium complex infections. Thirty healthy male and female volunteers were divided into five groups of six participants each: 18 received 300 mg/day of rifabutin, 12 in combination with therapeutic doses of either azithromycin or clarithromycin; the remaining 12 received azithromycin or clarithromycin alone. On day 10 the study was terminated because of adverse events, including severe neutropenia. Fourteen participants who received rifabutin developed neutropenia, including all 12 participants who received azithromycin or clarithromycin concomitantly. Analyses of serum revealed no apparent pharmacokinetic interaction between azithromycin and rifabutin. However, the mean concentrations of rifabutin and 25-O-desacetyl-rifabutin (an active metabolite) in participants who received clarithromycin and rifabutin concomitantly were more than 400% and 3,700%, respectively, of concentrations in those who received rifabutin alone. Physicians should be aware that recommended prophylactic doses of rifabutin may be associated with severe neutropenia within 2 weeks after initiation of therapy, and all patients receiving rifabutin, especially with clarithromycin, should be monitored carefully for neutropenia.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S C Bell, S L Senini, and J G McCormack Macrolides in cystic fibrosis Chronic Respiratory Disease, April 1, 2005; 2(2): 85 - 98. [Abstract] [PDF]

				S. K. Field, D. Fisher, and R. L. Cowie Mycobacterium avium complex Pulmonary Disease in Patients Without HIV Infection Chest, August 1, 2004; 126(2): 566 - 581. [Abstract] [Full Text] [PDF]

				American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662. [Full Text] [PDF]

				C. K. Finch, C. R. Chrisman, A. M. Baciewicz, and T. H. Self Rifampin and Rifabutin Drug Interactions: An Update Arch Intern Med, May 13, 2002; 162(9): 985 - 992. [Abstract] [Full Text] [PDF]

				R. Hafner, J. Bethel, H. C. Standiford, S. Follansbee, D. L. Cohn, R. E. Polk, L. Mole, R. Raasch, P. Kumar, D. Mushatt, et al. Tolerance and Pharmacokinetic Interactions of Rifabutin and Azithromycin Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1572 - 1577. [Abstract] [Full Text]